Spots Global Cancer Trial Database for myeloid leukemias
Every month we try and update this database with for myeloid leukemias cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Sirolimus in Combination With MEC in High Risk Myeloid Leukemias | NCT00780104 | Myeloid Leukemi... AML Leukemia CML | Rapamycin, Mito... Rapamycin + MEC | 18 Years - | Abramson Cancer Center at Penn Medicine | |
Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations | NCT00943943 | Acute Myelogeno... Leukemia | G-CSF Plerixafor Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
Sirolimus in Combination With MEC in High Risk Myeloid Leukemias | NCT00780104 | Myeloid Leukemi... AML Leukemia CML | Rapamycin, Mito... Rapamycin + MEC | 18 Years - | Abramson Cancer Center at Penn Medicine | |
Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations | NCT00943943 | Acute Myelogeno... Leukemia | G-CSF Plerixafor Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
Sirolimus in Combination With MEC in High Risk Myeloid Leukemias | NCT00780104 | Myeloid Leukemi... AML Leukemia CML | Rapamycin, Mito... Rapamycin + MEC | 18 Years - | Abramson Cancer Center at Penn Medicine | |
Sirolimus in Combination With MEC in High Risk Myeloid Leukemias | NCT00780104 | Myeloid Leukemi... AML Leukemia CML | Rapamycin, Mito... Rapamycin + MEC | 18 Years - | Abramson Cancer Center at Penn Medicine |